about
hRUL138, a novel human RNA-binding RING-H2 ubiquitin-protein ligaseA high level of mutation tolerance in the multifunctional sequence encoding the RNA encapsidation signal of an avian hepatitis B virus and slow evolution rate revealed by in vivo infectionSequence- and structure-specific determinants in the interaction between the RNA encapsidation signal and reverse transcriptase of avian hepatitis B virusesInhibition of Alpha Interferon Signaling by Hepatitis B VirusStable Human Hepatoma Cell Lines for Efficient Regulated Expression of Nucleoside/Nucleotide Analog Resistant and Vaccine Escape Hepatitis B Virus Variants and Woolly Monkey Hepatitis B VirusGeneration of covalently closed circular DNA of hepatitis B viruses via intracellular recycling is regulated in a virus specific manner.Hepatitis B virus replication: novel roles for virus-host interactions.Hepatitis C virus hypervariable region 1 variants presented on hepatitis B virus capsid-like particles induce cross-neutralizing antibodies.Simple confirmatory assay for anti-HBc reactivity.Full-length hepatitis B virus core protein packages viral and heterologous RNA with similarly high levels of cooperativityA SELEX-screened aptamer of human hepatitis B virus RNA encapsidation signal suppresses viral replication.Efficient Hsp90-independent in vitro activation by Hsc70 and Hsp40 of duck hepatitis B virus reverse transcriptase, an assumed Hsp90 client protein.Human hepatitis B virus production in avian cells is characterized by enhanced RNA splicing and the presence of capsids containing shortened genomesInvolvement of the host DNA-repair enzyme TDP2 in formation of the covalently closed circular DNA persistence reservoir of hepatitis B virusesTruncated active human matrix metalloproteinase-8 delivered by a chimeric adenovirus-hepatitis B virus vector ameliorates rat liver cirrhosis.Evidence for multiple distinct interactions between hepatitis B virus P protein and its cognate RNA encapsidation signal during initiation of reverse transcription.Molecular epidemiology and immunology of hepatitis B virus infection - an update.Whole-Chain Tick Saliva Proteins Presented on Hepatitis B Virus Capsid-Like Particles Induce High-Titered Antibodies with Neutralizing PotentialThe level of viral antigen presented by hepatocytes influences CD8 T-cell function.Duck hepatitis B virus: an invaluable model system for HBV infection.Extensive mutagenesis of the conserved box E motif in duck hepatitis B virus P protein reveals multiple functions in replication and a common structure with the primer grip in HIV-1 reverse transcriptaseCarbonyl J acid derivatives block protein priming of hepadnaviral P protein and DNA-dependent DNA synthesis activity of hepadnaviral nucleocapsids.Hepatitis B viruses: reverse transcription a different way.Native display of complete foreign protein domains on the surface of hepatitis B virus capsids.dNTP versus NTP discrimination by phenylalanine 451 in duck hepatitis B virus P protein indicates a common structure of the dNTP-binding pocket with other reverse transcriptases.Chaperones activate hepadnavirus reverse transcriptase by transiently exposing a C-proximal region in the terminal protein domain that contributes to epsilon RNA bindingHepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes.HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B.Host-targeting agents for treatment of hepatitis B virus infection.Few basepairing-independent motifs in the apical half of the avian HBV ε RNA stem-loop determine site-specific initiation of protein-priming.A Role for the Host DNA Damage Response in Hepatitis B Virus cccDNA Formation-and Beyond?Suppression of hepatitis B virus antigen production and replication by wild-type HBV dependently replicating HBV shRNA vectors in vitro and in vivo.Formation of a functional hepatitis B virus replication initiation complex involves a major structural alteration in the RNA template.Mapping of homologous interaction sites in the hepatitis B virus core protein.Quantitative assessment of the antiviral potencies of 21 shRNA vectors targeting conserved, including structured, hepatitis B virus sites.A sensitive procedure for mapping the boundaries of RNA elements binding in vitro translated proteins defines a minimal hepatitis B virus encapsidation signal.Hepatitis B and C virus coinfection: a novel model system reveals the absence of direct viral interference.Precore-mediated inhibition of hepatitis B virus progeny DNA synthesis.Stable HepG2- and Huh7-based human hepatoma cell lines for efficient regulated expression of infectious hepatitis B virus.Hepatitis B Virus-Infected HepG2hNTCP Cells Serve as a Novel Immunological Tool To Analyze the Antiviral Efficacy of CD8+ T Cells In Vitro.
P50
Q24292995-35D50C96-8F1C-4BA8-8A2F-52D20CD37749Q24606375-8CD5A2E3-79A5-4354-9067-64175A439E2EQ24673641-8B8F1A9F-9DE6-4C6F-835A-53EAAEC4AF04Q27478029-37C3C4AB-6184-4C80-920D-72F56469D003Q28551711-178EDBF8-0938-4544-B45E-3AAB11CD19DAQ33686965-AB039A14-F808-4E80-867E-36072397591FQ33749343-F2D2A757-2190-4645-ADFC-5F394ACAA94CQ33890011-E15CF3F8-4043-4A24-93A0-1CCCE2E66711Q33919322-AB486727-EF2E-49A4-A871-648C03BFF1C8Q33966563-5081B3D4-4550-49BA-A81A-07F030B135BCQ34085801-8FEE0E68-CEB0-4267-B8C9-BFC185D12599Q34212832-135F0D30-BC78-47D7-901C-EBE08299591FQ34279855-A64C856B-E80F-4BCB-A893-6D40A18BE14BQ34407460-37554B18-A6EE-4A88-92B7-F1BE0B38F2CFQ34542461-1572E48F-F859-4A38-94AB-F2EE54227ACCQ34974070-3988FADC-EFAB-4768-B723-07B221BA6AF9Q35059419-0CAD7D04-A57F-4FD4-BFA2-CA5EB558403AQ35767564-2B8D7C27-6741-4F75-A318-A57B0A04ED45Q35784981-532DC66D-9031-492E-B75C-92577E8FBA5CQ35941634-E921737D-6B03-4BC9-B0C6-85525D03207CQ36086762-17D3A73C-CE25-4255-A281-D35E499B52D6Q36246202-2E9EFA06-8E4B-481C-A745-023A417A4F5BQ37109700-4D1A6D1B-999E-42DE-8DA8-5C4DB31AE749Q37163704-0755A69C-576A-4569-8F94-F9BC64E74EE9Q38290803-245AA1A4-1E9D-4247-B2D8-BC2BE6FF4229Q38297666-0E02412A-6014-414C-ACA5-781FDD037BBDQ38310253-2A84A1EC-1394-4CE5-A56E-0F9F7B35E7C6Q38517843-4FEF5BAF-3EA4-4ECE-B2AB-C72DCE9FC904Q38564439-644FABBA-D9D0-405C-82EE-5FF75DF4B6AAQ38645882-28BDECB9-36AC-4EF9-9AD2-32139394AC59Q39322379-9B764D6A-A167-4780-84EC-C7E592354AAEQ39426235-DA0B86E9-AFDC-41CB-96A1-12F4D7C0A38DQ39576399-20B5E735-D288-4CC8-B373-8CD31985AFF0Q39580757-22FB77CC-EF0F-40C6-8F88-98083B97B4C0Q39713610-0FCF059F-893A-4701-9483-96D733E7F552Q39718010-E39B7D60-665C-446A-B829-4F5C39E18F34Q39990948-A2482799-E1E6-49FF-B829-7E63897F7DA0Q40045731-F801AFD2-11AC-4329-97B8-8071E4C129FFQ40239173-C09A71FD-7F22-410D-863D-0011B55CEED6Q40280446-7A490625-CDD4-4FE1-A4F1-78A708809AE7
P50
description
moleculair bioloog
@nl
researcher
@en
հետազոտող
@hy
name
Michael Nassal
@ast
Michael Nassal
@de
Michael Nassal
@en
Michael Nassal
@es
Michael Nassal
@nl
Michael Nassal
@sl
type
label
Michael Nassal
@ast
Michael Nassal
@de
Michael Nassal
@en
Michael Nassal
@es
Michael Nassal
@nl
Michael Nassal
@sl
prefLabel
Michael Nassal
@ast
Michael Nassal
@de
Michael Nassal
@en
Michael Nassal
@es
Michael Nassal
@nl
Michael Nassal
@sl
P227
P21
P214
5145971344732331209
P227
1094904546
P31
P496
0000-0003-2204-9158
P735
P7859
viaf-5145971344732331209